Observational analysis highlights diagnostic performance differences using multi-molecular imaging in pheochromocytoma, suggesting implications for treatment strategies.
A patient with multiple endocrine neoplasia 2A (MEN2A) and a suspicion of metastasized pheochromocytoma, underwent multi-molecular positron emission tomography (PET) imaging with the recently presented radiopharmaceutical [18F]-metafluorobenzylguanidine (mFBG), [68Ga]Ga-DOTA-TOC and [18F]F-dihydroxyphenylalanine (DOPA) as well as scintigraphy with [123I]-metaiodobenzylguanidine (mIBG). The methods showed different diagnostic performance, with the highest number of suspected malignant lesions detected by [18F]-mFBG-PET, and revealed insights into tumour heterogeneity.
No takes yet. Share an insight, caveat, or question.
Hedeer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: